This content is machine translated Gynecological oncology Current study results offer a chance of improved survival The Society of Gynecologic Oncology ‘s annual meeting on women’s cancer is an important medical event for ovarian and endometrial diseases. The clinical presentations at SGO provide practice-changing updates and…
View Post 5 min This content is machine translated Ovarian Cancer Algorithm supports maintenance therapy in advanced stages The standard treatment for newly diagnosed advanced ovarian cancer consists of cytoreductive surgery followed by platinum-based chemotherapy with or without bevacizumab. Maintenance therapy with PARP inhibitors and olaparib-bevacizumab has recently…
View Post 9 min This content is machine translated Ovarian tumors Therapy Update For both germ cell and epithelial ovarian tumors, the first line of therapy is surgery and chemotherapy. However, there has been a lot of progress over the last few years,…
View Post 3 min This content is machine translated Ovarian cancer and the immune system The choice of chemotherapy is crucial Chemotherapy-induced changes in the immune system can be used therapeutically in the era of immuno-oncology. Accurate characterization of immunologic effects of different agents, in addition to better risk management, will…
View Post 2 min This content is machine translated Advanced high-grade serous ovarian cancer. HRD+ tumors: first PARP inhibitor approved for first-line maintenance therapy As the first and only PARP inhibitor, olaparib was recently approved by swissmedic for first-line maintenance therapy in patients with advanced, HRD-positive ovarian cancer. The addition of olaparib to bevacizumab resulted…
View Post 5 min This content is machine translated Ovarian tumors Of PARP inhibitors, new agents and sexuality The treatment of ovarian cancer is in a constant state of flux with the ongoing development of new drugs such as PARP inhibitors. With increasing experience in the use of…
View Post 1 min This content is machine translated BRCA-mutated advanced ovarian cancer. PARP inhibitor shows long-term benefit in terms of PFS Ovarian cancer is the eighth leading cause of death among women with cancer worldwide. In Switzerland, approximately 620 patients are newly diagnosed with ovarian cancer each year. Approximately 22% of…
View Post 3 min This content is machine translated Ovarian Cancer Updated S3 guideline recommends PARP inhibitors and radiotherapy Because ovarian cancer generally has no specific symptoms, it is often diagnosed at late stages. The mortality risk is correspondingly high. In order to provide affected women with optimal therapy,…
View Post 4 min This content is machine translated Sponsored Content Maintenance therapy in ovarian cancer: considerations in the era of COVID-19. Cancer patients are considered a high-risk group in the Corona pandemic. But does this mean that one should now do without certain treatments? Prof. Dr. med. Viola Heinzelmann-Schwarz, Gynecological Tumor…
View Post 2 min This content is machine translated Editorial Swiss Oncology in Motion: Video-based online training courses Educational films in various modules for medical oncologists, hematologists and oncology specialists. Oncology is on the move – research is advancing rapidly and new insights into biology and therapy are…
View Post 8 min This content is machine translated Ovarian Cancer Treatment 2019: Important and new Ovarian cancer has become a chronic disease. Therapy sequences with surgery, additive and palliative systemic therapies, plus maintenance therapies in different lineages are complex. Discussing current data helps to translate…
